journal article·2020-01-08

Reactive Oxygen Species-Induced Aggregation of Nanozymes for Neuron Injury

Hua He, Xinjian Shi, Junying Wang, Xiaojuan Wang, Qian Wang, Daoyong Yu, Baosheng Ge, Xiaodong Zhang, Fang Huang

Publisher page

Abstract

Nanozymes show excellent enzyme activity and robust catalytic properties, but the targeting capability to disease organs is limited because of lack of specificity. Herein, we developed an ultrasmall (∼3 nm) organic nanozyme that can gradually aggregate under a reactive oxygen species (ROS)-rich environment via a spontaneous reaction, namely, ROS-induced aggregation. The size of nanozymes is 75 and 100 times higher than the original size under •OH and H2O2 environments without losing enzyme activity. In vitro experiments confirm that nanozymes prefer to aggregate in mitochondria under ROS-rich conditions. Importantly, the nanozymes show in situ ROS-induced aggregation in the brain, ∼9 times higher uptake than ordinary nanozymes, indicating their potential for treating ROS-related diseases in the central nervous system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanocluster Synthesis and Applications · Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Heavy Oil Processing and College of Chemical Engineering, China University of Petroleum (East China), Qingdao 266580, China

Department of Physics, School of Science, Tianjin University, Tianjin 300350, China

Funding

National Natural Science Foundation of China

References (44)

Show source-provided references
1. 10.1021/acs.chemrev.8b0067210.1021/acs.chemrev.8b00672 ↗
2. 10.1039/c8cs00457a10.1039/c8cs00457a ↗
3. 10.1038/nnano.2007.26010.1038/nnano.2007.260 ↗
4. 10.1038/nnano.2012.9110.1038/nnano.2012.91 ↗
5. 10.1002/anie.20141039810.1002/anie.201410398 ↗
6. 10.1002/anie.20170857310.1002/anie.201708573 ↗
7. 10.1021/jacs.5b1034610.1021/jacs.5b10346 ↗
8. 10.1038/s41467-018-03617-x10.1038/s41467-018-03617-x ↗
9. 10.1002/adma.20140023810.1002/adma.201400238 ↗
10. 10.1039/c5nr08358c10.1039/c5nr08358c ↗
11. 10.1002/anie.20171246910.1002/anie.201712469 ↗
12. 10.1002/chem.20180441910.1002/chem.201804419 ↗
13. 10.1021/acs.chemmater.8b0272610.1021/acs.chemmater.8b02726 ↗
14. 10.1038/s41467-018-03903-810.1038/s41467-018-03903-8 ↗
15. 10.1038/s41467-018-05798-x10.1038/s41467-018-05798-x ↗
16. 10.1021/acsnano.7b0774610.1021/acsnano.7b07746 ↗
17. 10.1021/acsnano.6b0032110.1021/acsnano.6b00321 ↗
18. 10.1021/acsnano.8b0804510.1021/acsnano.8b08045 ↗
19. 10.1039/c6cc07896f10.1039/c6cc07896f ↗
20. 10.1039/c4cc00328d10.1039/c4cc00328d ↗
21. 10.1021/acsnano.5b0131110.1021/acsnano.5b01311 ↗
22. 10.1021/nn302270b10.1021/nn302270b ↗
23. 10.1002/cphc.20110090610.1002/cphc.201100906 ↗
24. 10.1002/smll.20150391910.1002/smll.201503919 ↗
25. 10.1038/ncomms630110.1038/ncomms6301 ↗
26. 10.1002/anie.20160086810.1002/anie.201600868 ↗
27. 10.1021/acsnano.7b0342610.1021/acsnano.7b03426 ↗
28. 10.1038/nrneurol.2017.1310.1038/nrneurol.2017.13 ↗
29. 10.1016/j.nurt.2009.10.02110.1016/j.nurt.2009.10.021 ↗
30. 10.1021/nn102845t10.1021/nn102845t ↗
31. 10.1371/journal.pone.006181910.1371/journal.pone.0061819 ↗
32. 10.2165/11634020-000000000-0000010.2165/11634020-000000000-00000 ↗
33. 10.1021/nn302615f10.1021/nn302615f ↗
34. 10.1002/smll.20170371010.1002/smll.201703710 ↗
35. 10.1021/acs.nanolett.7b0509510.1021/acs.nanolett.7b05095 ↗
36. 10.1039/c5tb00570a10.1039/c5tb00570a ↗
37. 10.1021/acs.jafc.7b0224710.1021/acs.jafc.7b02247 ↗
38. 10.1021/jf030723c10.1021/jf030723c ↗
39. Anderson M. E. · 1985 · 548
40. 10.1021/nn501640q10.1021/nn501640q ↗
41. 10.1021/ja044171610.1021/ja0441716 ↗
42. 10.1016/s0955-0674(03)00002-410.1016/s0955-0674(03)00002-4 ↗
43. 10.1038/nchembio.60710.1038/nchembio.607 ↗
44. 10.1021/jacs.6b1101310.1021/jacs.6b11013 ↗